Hasil Pencarian - H. Quach

  • Menampilkan 1 - 17 hasil dari 17
Perbaiki Hasil
  1. 1
    A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells

    A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells oleh David H. Quach, Luis Becerra-Dominguez, Rayne H. Rouce, Cliona M. Rooney

    Diterbitkan 2019-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Egr3 dependent sympathetic target tissue innervation in the absence of neuron death.

    Egr3 dependent sympathetic target tissue innervation in the absence of neuron death. oleh Lin Li, Laurie C Eldredge, David H Quach, Avinash Honasoge, Katherine Gruner, Warren G Tourtellotte

    Diterbitkan 2011-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY

    P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDO... oleh H. Quach, X. Leleu, M.-V. Mateos, S. Z. Usmani, A. K. Nooka, A. Goldrick, R. Najdi, N. Shu, T. Facon

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Non-arteritic anterior ischemic and glaucomatous optic neuropathy: Implications for neuroretinal rim remodeling with disease severity.

    Non-arteritic anterior ischemic and glaucomatous optic neuropathy: Implications for neuroretinal rim remodeling with disease severity. oleh Brennan D Eadie, Oksana M Dyachok, Jack H Quach, Charles E Maxner, Paul E Rafuse, Lesya M Shuba, Jayme R Vianna, Balwantray C Chauhan, Marcelo T Nicolela

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    P946: A PHASE I/II SINGLE ARM STUDY OF BELANTAMAB MAFODOTIN, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: AMARC 19-02 BELACARD STUDY.

    P946: A PHASE I/II SINGLE ARM STUDY OF BELANTAMAB MAFODOTIN, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: AMARC 19-02 BELACARD STUDY. oleh M. Lasica, A. Spencer, P. Campbell, C. Wallington-Gates, N. Wong Doo, W. Janowski, G. McCaughan, A. Puliyayil, F. Yuen, K. Le, J. Reynolds, H. Quach

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    P941: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-6 ARM-A INTERIM ANALYSIS

    P941: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-6 ARM-A INTERIM... oleh H. Quach, M. Gironella, C. Lee, R. Popat, P. Cannell, R. S. Kasinathan, B. Chopra, R. Rogers, G. Ferron-Brady, S. Shafi-Harji, N. Patel, J. Opalinska, I. Gupta, B. Augustson

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES

    CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER... oleh H. Quach, A. Nooka, O. Samoylova, C.P. Venner, T. Facon, A. Spencer, S.Z. Usmani, K. Weisel, M. Mateos, K. Kim, S. Grosicki, K. Suzuki, S. Delimpasi, M. Obreja, A. Zahlten-Kumeli

    Diterbitkan 2020-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    P945: SUBCUTANEOUS ISATUXIMAB ADMINISTRATION BY AN ON-BODY DELIVERY SYSTEM IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: INTERIM PHASE 1B STUDY RESULTS

    P945: SUBCUTANEOUS ISATUXIMAB ADMINISTRATION BY AN ON-BODY DELIVERY SYSTEM IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: INTERIM... oleh H. Quach, G. Parmar, E. M. Ocio, H. M. Prince, A. Oriol, N. Tsukada, K. Sunami, P. Bories, C. Karanes, S. Madan, D. Semiond, M. Inchauspe, S. Macé, P. B. Musholt, F. Suzan, P. Moreau

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

    PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY M... oleh S. Delimpasi, H. Quach, M. Cavo, P. J. Ho, C. H.-S. Lee, A. Santoro, R. Schots, P. Vlummens, D. H. Yoon, S.-S. Yoon, C. D. Santos, D. Samineni, J. Huang, K. Wehrman, U. Patil, S. Sheikh, M. A. Dimopoulos

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)

    P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM) oleh E. Searle, H. Quach, S. Wong, L. Costa, C. Hulin, W. Janowski, J. Berdeja, S. Anguille, J. Matous, C. Touzeau, A. Michallet, M. Husnik, D. Vishwamitra, Z. Niu, J. Larsen, L. Chen, J. Goldberg, R. Popat, A. Spencer

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3

    P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR... oleh A. M. Lesokhin, B. Arnulf, R. Niesvizky, M. Mohty, N. J. Bahlis, M. H. Tomasson, P. Rodrίguez-Otero, H. Quach, N. S. Raje, S. Iida, M.-S. Raab, A. Czibere, S. Sullivan, E. Leip, A. Viqueira, X. Leleu

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Pathological Endogenous α-Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy

    Pathological Endogenous α-Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy oleh Seiji Kaji, Takakuni Maki, Hisanori Kinoshita, Norihito Uemura, Takashi Ayaki, Yasuhiro Kawamoto, Takahiro Furuta, Makoto Urushitani, Masato Hasegawa, Yusuke Kinoshita, Yuichi Ono, Xiaobo Mao, Tran H. Quach, Kazuhiro Iwai, Valina L. Dawson, Ted M. Dawson, Ryosuke Takahashi

    Diterbitkan 2018-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-5 STUDY

    P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRM... oleh A. Nooka, S. Lonial, S. Grosicki, M. Hus, K. Song, T. Facon, N. S. Callander, V. Ribrag, K. Uttervall, H. Quach, V. Vorobyev, C.-K. Min, S. Cheng, L. M. Smith, J. Yu, T. Collingwood, B. Holkova, B. E. Kremer, I. V. Gupta, P. G. Richardson, M. C. Minnema

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY

    P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA... oleh K. Weisel, S. Kumar, P. Moreau, N. Bahlis, T. Facon, T. Plesner, R. Orlowski, S. Basu, H. Nahi, C. Hulin, H. Quach, H. Goldschmidt, M. O’Dwyer, A. Perrot, C. Venner, N. Raje, M. Tiab1, M. Macro, L. Frenzel, X. Leleu, H. Pei, M Krevvata, R Carson, F. Borgsten, S. Usmani

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

    P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA oleh S Usmani, A Alonso, H Quach, Y Koh, A Guenther, CK Min, X Leleu, AO Abdallah, A Oriol, B Bessemer, M Garg, I Sandhu, K Weisel, E Ocio San Miguel, M Cavo, X Zhou, M Kaisermann, L Mis, D Williams, A Yeakey, G Ferron-Brady, D Figueroa, B Kremer, I Gupta, W Janowski

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

    P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA oleh S. Z. Usmani, M. Mielnik, Y. Koh, A. Alonso Alonso, X. Leleu, H. Quach, C.-K. Min, W. Janowski, A.-O. Abdallah, M. Garg, I. Sandhu, E. M. Ocio San Miguel, A. Oriol, P. Rodriquez-Otero, K. Ramasamy, K. Weisel, B. Besemer, M. Cavo, X. L. Zhou, M. C. Kaisermann, C. M. Bego Marques, D. Williams, F. Carreno, B. E. Kremer, I. V. Gupta, M. Hus

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    P1573: VARIATION IN USE OF IMMUNOGLOBULIN AND IMPACT ON SURVIVAL IN MULTIPLE MYELOMA: A REPORT FROM THE AUSTRALIA/NEW ZEALAND (ANZ) AND ASIA-PACIFIC (APAC) MYELOMA AND RELATED DISEASES REGISTRIES (MRDR)

    P1573: VARIATION IN USE OF IMMUNOGLOBULIN AND IMPACT ON SURVIVAL IN MULTIPLE MYELOMA: A REPORT FROM THE AUSTRALIA/NEW ZEALAND (ANZ) AND ASIA-PACIFIC (APAC) MYELOMA AND RELATED DISE... oleh K. L. Chai, C. Wellard, N. Aoki, E. M. Moore, B. Augustson, A. Bapat, H. A. Blacklock, W. J. Chng, R. Cooke, C. Forsyth, N. Hamad, S. J. Harrison, P. J. Ho, J. Hocking, I. H. Kerridge, J. S. Kim, K. Kim, T. King, G. J. McCaughan, P. Mollee, C. O. Morrissey, N. Murphy, H. Quach, X. N. Tan, A. Tso, K. Wong, A. Spencer, E. M. Wood, Z. K. McQuilten

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: